Restricted Cusp Motion in Newly Implanted Tricuspid Bioprostheses: Incidence, Predictors, and Impact on Survival

Abstract

ObjectiveThis study aimed to investigate the occurrence of restricted cusp motion (RCM) at the time of bioprosthetic tricuspid valve replacement (TVR) and analyzed associated risk factors and outcomes. MethodsThis study involved adult patients who underwent TVR with a bioprosthesis at our institution between 2012 and 2022. Bioprosthetic cusp motion was analyzed de-novo through a detailed review of intraoperative transesophageal echocardiograms (TEE). Two models of porcine valves were implanted, the Hancock II bioprosthesis (Medtronic, Inc, Minneapolis, Minnesota) and the St. Jude Epic bioprosthesis (St. Jude Medical, St. Paul, Minnesota). ResultsAmong the 476 patients who met the inclusion criteria, RCM was identified on the immediate post-bypass TEE in 150 (31.5%); there was complete immobility of the cusp in 63 patients (13.2%) and limited movement of a cusp in 87 patients (18.3%). In a multivariable logistic regression analysis, the Hancock II model (OR 6.15, p<0.001), a larger orifice area (per IQR increase, OR 1.58, p=0.017), a smaller body surface area (per IQR increase, OR 0.68, p=0.040), and a lower ejection fraction (per IQR increase, OR 0.60, p=0.033) were independently associated with having RCM. Cox regression adjusting for 15 covariates revealed that RCM at time of TVR was independently associated with an increased risk of mortality (HR 1.35, p=0.049). ConclusionsThis study revealed a high incidence of restricted cusp motion in bioprosthetic valves in the tricuspid position detected shortly post-implantation, which was associated with increased late mortality. To reduce the probability of restricted cusp motion, it is important to select the appropriate prosthesis model and size, particularly in small patients.